| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Evidence-based Practice |
1 From the National Council of Research, Istituto Metodologie Diagnostiche Avanzate, Palermo, Italy (C.C); Department of Gastroenterology, Section of Clinical Medicine (C.C., A.C.) and Department of General Medicine and Pneumology (A.O., M.A., M.C.), University of Palermo, Piazza delle Cliniche 2, 90127 Palermo, Italy; Department of Experimental Medicine, Clinica G. Salvatore, University of Catanzaro, Italy (F.S.); Department of Internal Medicine, Cardiology, and Hepatology, University of Bologna, Italy (F.T., P.A.); and Fox Chase Cancer Center, Philadelphia, Pa (L.S.). Received July 23, 2001; revision requested September 28; revision received November 8; accepted January 8, 2002. Address correspondence to C.C. (e-mail: camma@ismeda.pa.cnr.it).
PURPOSE: To review the available evidence of chemoembolization for unresectable hepatocellular carcinoma (HCC).
MATERIALS AND METHODS: Computerized bibliographic searches with MEDLINE and CANCERLIT databases from 1980 through 2000 were supplemented with manual searches, with the keywords "hepatocellular carcinoma," "liver cell carcinoma," "randomized controlled trial [RCT]," and "chemoembolization." Studies were included if patients with unresectable HCC were enrolled and if they were RCTs in which chemoembolization was compared with nonactive treatment (five RCTs) or if different transarterial modalities of therapy (13 RCTs) were compared. Data were extracted from each RCT according to the intention-to-treat method. Five of the RCTs with a nonactive treatment arm were combined by using the random-effects model, whereas all 18 RCTs were pooled from meta–regression analysis.
RESULTS: Chemoembolization significantly reduced the overall 2-year mortality rate (odds ratio, 0.54; 95% CI: 0.33, 0.89; P = .015) compared with nonactive treatment. Analysis of comparative RCTs helped to predict that overall mortality was significantly lower in patients treated with transarterial embolization (TAE) than in those treated with transarterial chemotherapy (odds ratio, 0.72; 95% CI: 0.53, 0.98; P = .039) and that there is no evidence that transarterial chemoembolization is more effective than TAE (odds ratio, 1.007; 95% CI: 0.79, 1.27; P = .95), which suggests that the addition of an anticancer drug did not improve the therapeutic benefit.
CONCLUSION: In patients with unresectable HCC, chemoembolization significantly improved the overall 2-year survival compared with nonactive treatment, but the magnitude of the benefit is relatively small.
© RSNA, 2002
Index terms: Efficacy study • Liver neoplasms, 761.323 • Liver neoplasms, chemotherapeutic embolization, 761.1264, 761.1266 • Radiology and radiologists, outcomes studies
This article has been cited by other articles:
|
|
 |
|
  J. Iwazawa, S. Ohue, T. Mitani, H. Abe, N. Hashimoto, M. Hamuro, and K. Nakamura Identifying Feeding Arteries During TACE of Hepatic Tumors: Comparison of C-Arm CT and Digital Subtraction Angiography Am. J. Roentgenol., April 1, 2009; 192(4): 1057 - 1063. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. K. Abou-Alfa Commentary: Sorafenib--The End of a Long Journey in Search of Systemic Therapy for Hepatocellular Carcinoma, or the Beginning? Oncologist, January 1, 2009; 14(1): 92 - 94. [Full Text] [PDF]
|
|
|
|
 |
|
 J. T. Heckman, M. B. deVera, J. W. Marsh, P. Fontes, N. B. Amesur, S. E. Holloway, M. Nalesnik, D. A. Geller, J. L. Steel, and T. C. Gamblin Bridging Locoregional Therapy for Hepatocellular Carcinoma Prior to Liver Transplantation Ann. Surg. Oncol., November 1, 2008; 15(11): 3169 - 3177. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Buijs, J. A. Vossen, C. Frangakis, K. Hong, C. S. Georgiades, Y. Chen, E. Liapi, and J.-F. H. Geschwind Nonresectable Hepatocellular Carcinoma: Long-term Toxicity in Patients Treated with Transarterial Chemoembolization--Single-Center Experience Radiology, October 1, 2008; 249(1): 346 - 354. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G J Munneke Interventional radiology in liver cancer Imaging, September 1, 2008; 20(3): 185 - 193. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Igaki, K. Nakagawa, K. Shiraishi, S. Shiina, N. Kokudo, A. Terahara, H. Yamashita, N. Sasano, M. Omata, and K. Ohtomo Three-dimensional Conformal Radiotherapy for Hepatocellular Carcinoma with Inferior Vena Cava Invasion Jpn. J. Clin. Oncol., June 1, 2008; 38(6): 438 - 444. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Belghiti, B. I. Carr, P. D. Greig, R. Lencioni, and R. T. Poon Treatment before Liver Transplantation for HCC Ann. Surg. Oncol., April 1, 2008; 15(4): 993 - 1000. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-L. Chong, S.-F. Huang, C.-p. Hu, Y.-L. Chen, H.-Y. Chou, G.-Y. Chau, J.-Y. Shew, Y.-L. Tsai, C.-T. Chen, C. Chang, et al. Decreased Expression of UK114 Is Related to the Differentiation Status of Human Hepatocellular Carcinoma Cancer Epidemiol. Biomarkers Prev., March 1, 2008; 17(3): 535 - 542. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. V. Tse, M. Hawkins, G. Lockwood, J. J. Kim, B. Cummings, J. Knox, M. Sherman, and L. A. Dawson Phase I Study of Individualized Stereotactic Body Radiotherapy for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma J. Clin. Oncol., February 1, 2008; 26(4): 657 - 664. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J Pildal, A Hrobjartsson, K. Jorgensen, J Hilden, D. Altman, and P. Gotzsche Impact of allocation concealment on conclusions drawn from meta-analyses of randomized trials Int. J. Epidemiol., August 1, 2007; 36(4): 847 - 857. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Kumar, D. N. Srivastava, T. T. M. Chau, H. D. Long, C. Bal, P. Chandra, L. T. Chien, N. V. Hoa, S. Thulkar, S. Sharma, et al. Inoperable Hepatocellular Carcinoma: Transarterial 188Re HDD-Labeled Iodized Oil for Treatment--Prospective Multicenter Clinical Trial Radiology, May 1, 2007; 243(2): 509 - 519. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Liapi and J.-F. H. Geschwind Transcatheter and Ablative Therapeutic Approaches for Solid Malignancies J. Clin. Oncol., March 10, 2007; 25(8): 978 - 986. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Mahmood Can a Clinically Used Chemoembolization Vehicle Improve Transgene Delivery? Radiology, September 1, 2006; 240(3): 619 - 620. [Full Text] [PDF]
|
|
|
|
 |
|
 M. C. Ralstin, E. A. Gage, M. T. Yip-Schneider, P. J. Klein, E. A. Wiebke, and C. M. Schmidt Parthenolide Cooperates with NS398 to Inhibit Growth of Human Hepatocellular Carcinoma Cells through Effects on Apoptosis and G0-G1 Cell Cycle Arrest Mol. Cancer Res., June 1, 2006; 4(6): 387 - 399. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Hong, A. Khwaja, E. Liapi, M. S. Torbenson, C. S. Georgiades, and J.-F. H. Geschwind New Intra-arterial Drug Delivery System for the Treatment of Liver Cancer: Preclinical Assessment in a Rabbit Model of Liver Cancer Clin. Cancer Res., April 15, 2006; 12(8): 2563 - 2567. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. S.K. Mok, W. Yeo, S. Yu, P. Lai, H. L.Y. Chan, A. T.C. Chan, J. W.Y. Lau, H. Wong, N. Leung, E. P. Hui, et al. An Intensive Surveillance Program Detected a High Incidence of Hepatocellular Carcinoma Among Hepatitis B Virus Carriers With Abnormal Alpha-Fetoprotein Levels or Abdominal Ultrasonography Results J. Clin. Oncol., November 1, 2005; 23(31): 8041 - 8047. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Staunton, J. D. Dodd, P. A. McCormick, and D. E. Malone Finding Evidence-based Answers to Practical Questions in Radiology: Which Patients with Inoperable Hepatocellular Carcinoma Will Survive Longer after Transarterial Chemoembolization? Radiology, November 1, 2005; 237(2): 404 - 413. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Kan, S. Kobayashi, S. Phongkitkarun, and C. Charnsangavej Functional CT Quantification of Tumor Perfusion after Transhepatic Arterial Embolization in a Rat Model Radiology, October 1, 2005; 237(1): 144 - 150. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Wirth, F. Kuhnel, B. Fleischmann-Mundt, N. Woller, M. Djojosubroto, K. L. Rudolph, M. Manns, L. Zender, and S. Kubicka Telomerase-Dependent Virotherapy Overcomes Resistance of Hepatocellular Carcinomas against Chemotherapy and Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand by Elimination of Mcl-1 Cancer Res., August 15, 2005; 65(16): 7393 - 7402. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Feng, B. A. Kienitz, C. Matsumoto, J. Bruce, M. Sisti, H. Duong, and J. Pile-Spellman Feasibility of Using Hyperosmolar Mannitol as a Liquid Tumor Embolization Agent AJNR Am. J. Neuroradiol., June 1, 2005; 26(6): 1405 - 1412. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. N. Goldberg, C. J. Grassi, J. F. Cardella, J. W. Charboneau, G. D. Dodd II, D. E. Dupuy, D. Gervais, A. R. Gillams, R. A. Kane, F. T. Lee Jr, et al. Image-guided Tumor Ablation: Standardization of Terminology and Reporting Criteria Radiology, June 1, 2005; 235(3): 728 - 739. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. B. Thomas and A. X. Zhu Hepatocellular Carcinoma: The Need for Progress J. Clin. Oncol., May 1, 2005; 23(13): 2892 - 2899. [Full Text] [PDF]
|
|
|
|
|
|
P. V. Pandharipande, G. A. Krinsky, H. Rusinek, and V. S. Lee Perfusion Imaging of the Liver: Current Challenges and Future Goals Radiology, March 1, 2005; 234(3): 661 - 673. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Feng, C. L. Dumoulin, S. Dashnaw, R. D. Darrow, R. L. DeLaPaz, P. L. Bishop, and J. Pile-Spellman Feasibility of Stent Placement in Carotid Arteries with Real-time MR Imaging Guidance in Pigs Radiology, February 1, 2005; 234(2): 558 - 562. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Seror, G. N'Kontchou, D. Haddar, M. Dordea, Y. Ajavon, N. Ganne, J. C. Trinchet, M. Beaugrand, and N. Sellier Large Infiltrative Hepatocellular Carcinomas: Treatment with Percutaneous Intraarterial Ethanol Injection Alone or in Combination with Conventional Percutaneous Ethanol Injection Radiology, January 1, 2005; 234(1): 299 - 309. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A R Gillams Liver ablation therapy Br. J. Radiol., September 1, 2004; 77(921): 713 - 723. [Full Text] [PDF]
|
|
|
|
|
|
J. M. Llovet, J. Bruix, C. Camma, M. Cottone, A. Craxi, and R. P. Myers Unresectable Hepatocellular Carcinoma: Meta-Analysis of Arterial Embolization [letter] * Dr Camma and colleagues respond: * Dr Myers responds: Radiology, January 1, 2004; 230(1): 300 - 302. [Full Text] [PDF]
|
|
|
|
|
|
K. Stuart Chemoembolization in the Management of Liver Tumors Oncologist, October 1, 2003; 8(5): 425 - 437. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. N. Goldberg, J. W. Charboneau, G. D. Dodd III, D. E. Dupuy, D. A. Gervais, A. R. Gillams, R. A. Kane, F. T. Lee Jr, T. Livraghi, J. P. McGahan, et al. Image-guided Tumor Ablation: Proposal for Standardization of Terms and Reporting Criteria Radiology, August 1, 2003; 228(2): 335 - 345. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Qiu, D. David, B. Zhou, P. G. Chu, B. Zhang, M. Wu, J. Xiao, T. Han, Z. Zhu, T. Wang, et al. Down-Regulation of Growth Arrest DNA Damage-Inducible Gene 45{beta} Expression Is Associated with Human Hepatocellular Carcinoma Am. J. Pathol., June 1, 2003; 162(6): 1961 - 1974. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. P. Myers, C. Camma, F. Schepis, M. Cottone, and A. Craxi Meta-analysis of Transarterial Embolization in Patients with Unresectable Hepatocellular Carcinoma [letter] * Dr Camma and colleagues respond: Radiology, May 1, 2003; 227(2): 611 - 613. [Full Text] [PDF]
|
|
